The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 11, 2020
Filed:
Sep. 20, 2017
Applicants:
Ganymed Pharmaceuticals Ag, Mainz, DE;
Johannes Gutenberg-universitat Mainz, Mainz, DE;
Inventors:
Ugur Sahin, Mainz, DE;
Özlem Türeci, Mainz, DE;
Dirk Usener, Wiesbaden, DE;
Stefan Fritz, Flonheim, DE;
Christoph Uherek, Ginsheim, DE;
Gunda Brandenburg, Mainz, DE;
Harald-Gerhard Geppert, Hannover, DE;
Anja Kristina Schröder, Mainz, DE;
Phillippe Thiel, Planegg, DE;
Assignees:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); A01N 63/00 (2020.01); C07K 16/18 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); C07K 16/30 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6807 (2017.08); A61K 47/6809 (2017.08); A61K 47/6813 (2017.08); A61K 47/6821 (2017.08); A61K 47/6823 (2017.08); A61K 47/6829 (2017.08); A61K 47/6851 (2017.08); A61K 47/6859 (2017.08); A61K 47/6863 (2017.08); A61K 47/6869 (2017.08); A61K 51/1063 (2013.01); C07K 16/28 (2013.01); C07K 16/3046 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01);
Abstract
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.